Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS)

D. Binda; E. K. Vanhoutte; G. Cavaletti; D. R. Cornblath; T. J. Postma; B. Frigeni; P. Alberti; J. Bruna; R. Velasco; A. A. Argyriou; H. P. Kalofonos; D. Psimaras; D. Ricard; A. Pace; E. Galie; C. Briani; C. Dalla Torre; R. I. Lalisang; W. Boogerd; D. Brandsma; S. Koeppen; J. Hense; D. Storey; S. Kerrigan; A. Schenone; S. Fabbri; E. Rossi; M. G. Valsecchi; C. G. Faber; I. S. J. Merkies; S. Galimberti; F. Lanzani; L. Mattavelli; M. L. Piatti; P. Bidoli; M. Cazzaniga; D. Cortinovis; M. Lucchetta; M. Campagnolo; M. Bakkers; B. Brouwer; R. Grant; L. Reni; B. Piras; A. Pessino; L. Padua; G. Granata; M. Leandri; I. Ghignotti; R. Plasmati; F. Pastorelli; J. J. Heimans; M. Eurelings; R. J. Meijer; W. Grisold; E. Lindeck Pozza; A. Mazzeo; A. Toscano; M. Russo; C. Tomasello; G. Altavilla; M. Penas Prado; C. Dominguez Gonzalez; S. G. Dorsey

doi:10.1016/j.ejca.2013.04.004

Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS)

D. Binda, E. K. Vanhoutte, G. Cavaletti, D. R. Cornblath, T. J. Postma, B. Frigeni, P. Alberti, J. Bruna, R. Velasco, A. A. Argyriou, H. P. Kalofonos, D. Psimaras, D. Ricard, A. Pace, E. Galie, C. Briani, C. Dalla Torre, R. I. Lalisang, W. Boogerd, D. BrandsmaS. Koeppen, J. Hense, D. Storey, S. Kerrigan, A. Schenone, S. Fabbri, E. Rossi, M. G. Valsecchi, C. G. Faber, I. S. J. Merkies^*, S. Galimberti, F. Lanzani, L. Mattavelli, M. L. Piatti, P. Bidoli, M. Cazzaniga, D. Cortinovis, M. Lucchetta, M. Campagnolo, M. Bakkers, B. Brouwer, R. Grant, L. Reni, B. Piras, A. Pessino, L. Padua, G. Granata, M. Leandri, I. Ghignotti, R. Plasmati, F. Pastorelli, J. J. Heimans, M. Eurelings, R. J. Meijer, W. Grisold, E. Lindeck Pozza, A. Mazzeo, A. Toscano, M. Russo, C. Tomasello, G. Altavilla, M. Penas Prado, C. Dominguez Gonzalez, S. G. Dorsey

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common neurological side-effect of cancer treatment and may lead to declines in patients' daily functioning and quality of life. To date, there are no modern clinimetrically well-evaluated outcome measures available to assess disability in CIPN patients. The objective of the study was to develop an interval-weighted scale to capture activity limitations and participation restrictions in CIPN patients using the Rasch methodology and to determine its validity and reliability properties. A preliminary Rasch-built Overall Disability Scale (pre-R-ODS) comprising 146 items was assessed twice (interval: 2-3 weeks; test-retest reliability) in 281 CIPN patients with a stable clinical condition. The obtained data were subjected to Rasch analyses to determine whether model expectations would be met, and if necessarily, adaptations were made to obtain proper model fit (internal validity). External validity was obtained by correlating the CIPN-R-ODS with the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) neuropathy scales and the Pain-Intensity Numeric-Rating-Scale (PI-NRS). The preliminary R-ODS did not meet Rasch model's expectations. Items displaying misfit statistics, disordered thresholds, item bias or local dependency were systematically removed. The final CIPN-R-ODS consisting of 28 items fulfilled all the model's expectations with proper validity and reliability, and was unidimensional. The final CIPN-R-ODS is a Rasch-built disease-specific, interval measure suitable to detect disability in CIPN patients and bypasses the shortcomings of classical test theory ordinal-based measures. Its use is recommended in future clinical trials in CIPN.

Original language	English
Pages (from-to)	2910-2918
Journal	European Journal of Cancer
Volume	49
Issue number	13
DOIs	https://doi.org/10.1016/j.ejca.2013.04.004
Publication status	Published - Sept 2013

Keywords

Chemotherapy
Peripheral neuropathy
Disability evaluation
Patient questionnaire

Access to Document

10.1016/j.ejca.2013.04.004

Cite this

Binda, D., Vanhoutte, E. K., Cavaletti, G., Cornblath, D. R., Postma, T. J., Frigeni, B., Alberti, P., Bruna, J., Velasco, R., Argyriou, A. A., Kalofonos, H. P., Psimaras, D., Ricard, D., Pace, A., Galie, E., Briani, C., Torre, C. D., Lalisang, R. I., Boogerd, W., ... Dorsey, S. G. (2013). Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). European Journal of Cancer, 49(13), 2910-2918. https://doi.org/10.1016/j.ejca.2013.04.004

@article{a41c8d7d01094286a3c25f9c7b78ffed,

title = "Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS)",

abstract = "Chemotherapy-induced peripheral neuropathy (CIPN) is a common neurological side-effect of cancer treatment and may lead to declines in patients' daily functioning and quality of life. To date, there are no modern clinimetrically well-evaluated outcome measures available to assess disability in CIPN patients. The objective of the study was to develop an interval-weighted scale to capture activity limitations and participation restrictions in CIPN patients using the Rasch methodology and to determine its validity and reliability properties. A preliminary Rasch-built Overall Disability Scale (pre-R-ODS) comprising 146 items was assessed twice (interval: 2-3 weeks; test-retest reliability) in 281 CIPN patients with a stable clinical condition. The obtained data were subjected to Rasch analyses to determine whether model expectations would be met, and if necessarily, adaptations were made to obtain proper model fit (internal validity). External validity was obtained by correlating the CIPN-R-ODS with the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) neuropathy scales and the Pain-Intensity Numeric-Rating-Scale (PI-NRS). The preliminary R-ODS did not meet Rasch model's expectations. Items displaying misfit statistics, disordered thresholds, item bias or local dependency were systematically removed. The final CIPN-R-ODS consisting of 28 items fulfilled all the model's expectations with proper validity and reliability, and was unidimensional. The final CIPN-R-ODS is a Rasch-built disease-specific, interval measure suitable to detect disability in CIPN patients and bypasses the shortcomings of classical test theory ordinal-based measures. Its use is recommended in future clinical trials in CIPN. ",

keywords = "Chemotherapy, Peripheral neuropathy, Disability evaluation, Patient questionnaire",

author = "D. Binda and Vanhoutte, {E. K.} and G. Cavaletti and Cornblath, {D. R.} and Postma, {T. J.} and B. Frigeni and P. Alberti and J. Bruna and R. Velasco and Argyriou, {A. A.} and Kalofonos, {H. P.} and D. Psimaras and D. Ricard and A. Pace and E. Galie and C. Briani and Torre, {C. Dalla} and Lalisang, {R. I.} and W. Boogerd and D. Brandsma and S. Koeppen and J. Hense and D. Storey and S. Kerrigan and A. Schenone and S. Fabbri and E. Rossi and Valsecchi, {M. G.} and Faber, {C. G.} and Merkies, {I. S. J.} and S. Galimberti and F. Lanzani and L. Mattavelli and Piatti, {M. L.} and P. Bidoli and M. Cazzaniga and D. Cortinovis and M. Lucchetta and M. Campagnolo and M. Bakkers and B. Brouwer and R. Grant and L. Reni and B. Piras and A. Pessino and L. Padua and G. Granata and M. Leandri and I. Ghignotti and R. Plasmati and F. Pastorelli and Heimans, {J. J.} and M. Eurelings and Meijer, {R. J.} and W. Grisold and Pozza, {E. Lindeck} and A. Mazzeo and A. Toscano and M. Russo and C. Tomasello and G. Altavilla and Prado, {M. Penas} and {Dominguez Gonzalez}, C. and Dorsey, {S. G.}",

year = "2013",

month = sep,

doi = "10.1016/j.ejca.2013.04.004",

language = "English",

volume = "49",

pages = "2910--2918",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "ELSEVIER SCI LTD",

number = "13",

}

Binda, D, Vanhoutte, EK, Cavaletti, G, Cornblath, DR, Postma, TJ, Frigeni, B, Alberti, P, Bruna, J, Velasco, R, Argyriou, AA, Kalofonos, HP, Psimaras, D, Ricard, D, Pace, A, Galie, E, Briani, C, Torre, CD, Lalisang, RI, Boogerd, W, Brandsma, D, Koeppen, S, Hense, J, Storey, D, Kerrigan, S, Schenone, A, Fabbri, S, Rossi, E, Valsecchi, MG, Faber, CG, Merkies, ISJ, Galimberti, S, Lanzani, F, Mattavelli, L, Piatti, ML, Bidoli, P, Cazzaniga, M, Cortinovis, D, Lucchetta, M, Campagnolo, M, Bakkers, M, Brouwer, B, Grant, R, Reni, L, Piras, B, Pessino, A, Padua, L, Granata, G, Leandri, M, Ghignotti, I, Plasmati, R, Pastorelli, F, Heimans, JJ, Eurelings, M, Meijer, RJ, Grisold, W, Pozza, EL, Mazzeo, A, Toscano, A, Russo, M, Tomasello, C, Altavilla, G, Prado, MP, Dominguez Gonzalez, C & Dorsey, SG 2013, 'Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS)', European Journal of Cancer, vol. 49, no. 13, pp. 2910-2918. https://doi.org/10.1016/j.ejca.2013.04.004

TY - JOUR

T1 - Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS)

AU - Binda, D.

AU - Vanhoutte, E. K.

AU - Cavaletti, G.

AU - Cornblath, D. R.

AU - Postma, T. J.

AU - Frigeni, B.

AU - Alberti, P.

AU - Bruna, J.

AU - Velasco, R.

AU - Argyriou, A. A.

AU - Kalofonos, H. P.

AU - Psimaras, D.

AU - Ricard, D.

AU - Pace, A.

AU - Galie, E.

AU - Briani, C.

AU - Torre, C. Dalla

AU - Lalisang, R. I.

AU - Boogerd, W.

AU - Brandsma, D.

AU - Koeppen, S.

AU - Hense, J.

AU - Storey, D.

AU - Kerrigan, S.

AU - Schenone, A.

AU - Fabbri, S.

AU - Rossi, E.

AU - Valsecchi, M. G.

AU - Faber, C. G.

AU - Merkies, I. S. J.

AU - Galimberti, S.

AU - Lanzani, F.

AU - Mattavelli, L.

AU - Piatti, M. L.

AU - Bidoli, P.

AU - Cazzaniga, M.

AU - Cortinovis, D.

AU - Lucchetta, M.

AU - Campagnolo, M.

AU - Bakkers, M.

AU - Brouwer, B.

AU - Grant, R.

AU - Reni, L.

AU - Piras, B.

AU - Pessino, A.

AU - Padua, L.

AU - Granata, G.

AU - Leandri, M.

AU - Ghignotti, I.

AU - Plasmati, R.

AU - Pastorelli, F.

AU - Heimans, J. J.

AU - Eurelings, M.

AU - Meijer, R. J.

AU - Grisold, W.

AU - Pozza, E. Lindeck

AU - Mazzeo, A.

AU - Toscano, A.

AU - Russo, M.

AU - Tomasello, C.

AU - Altavilla, G.

AU - Prado, M. Penas

AU - Dominguez Gonzalez, C.

AU - Dorsey, S. G.

PY - 2013/9

Y1 - 2013/9

N2 - Chemotherapy-induced peripheral neuropathy (CIPN) is a common neurological side-effect of cancer treatment and may lead to declines in patients' daily functioning and quality of life. To date, there are no modern clinimetrically well-evaluated outcome measures available to assess disability in CIPN patients. The objective of the study was to develop an interval-weighted scale to capture activity limitations and participation restrictions in CIPN patients using the Rasch methodology and to determine its validity and reliability properties. A preliminary Rasch-built Overall Disability Scale (pre-R-ODS) comprising 146 items was assessed twice (interval: 2-3 weeks; test-retest reliability) in 281 CIPN patients with a stable clinical condition. The obtained data were subjected to Rasch analyses to determine whether model expectations would be met, and if necessarily, adaptations were made to obtain proper model fit (internal validity). External validity was obtained by correlating the CIPN-R-ODS with the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) neuropathy scales and the Pain-Intensity Numeric-Rating-Scale (PI-NRS). The preliminary R-ODS did not meet Rasch model's expectations. Items displaying misfit statistics, disordered thresholds, item bias or local dependency were systematically removed. The final CIPN-R-ODS consisting of 28 items fulfilled all the model's expectations with proper validity and reliability, and was unidimensional. The final CIPN-R-ODS is a Rasch-built disease-specific, interval measure suitable to detect disability in CIPN patients and bypasses the shortcomings of classical test theory ordinal-based measures. Its use is recommended in future clinical trials in CIPN.

AB - Chemotherapy-induced peripheral neuropathy (CIPN) is a common neurological side-effect of cancer treatment and may lead to declines in patients' daily functioning and quality of life. To date, there are no modern clinimetrically well-evaluated outcome measures available to assess disability in CIPN patients. The objective of the study was to develop an interval-weighted scale to capture activity limitations and participation restrictions in CIPN patients using the Rasch methodology and to determine its validity and reliability properties. A preliminary Rasch-built Overall Disability Scale (pre-R-ODS) comprising 146 items was assessed twice (interval: 2-3 weeks; test-retest reliability) in 281 CIPN patients with a stable clinical condition. The obtained data were subjected to Rasch analyses to determine whether model expectations would be met, and if necessarily, adaptations were made to obtain proper model fit (internal validity). External validity was obtained by correlating the CIPN-R-ODS with the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) neuropathy scales and the Pain-Intensity Numeric-Rating-Scale (PI-NRS). The preliminary R-ODS did not meet Rasch model's expectations. Items displaying misfit statistics, disordered thresholds, item bias or local dependency were systematically removed. The final CIPN-R-ODS consisting of 28 items fulfilled all the model's expectations with proper validity and reliability, and was unidimensional. The final CIPN-R-ODS is a Rasch-built disease-specific, interval measure suitable to detect disability in CIPN patients and bypasses the shortcomings of classical test theory ordinal-based measures. Its use is recommended in future clinical trials in CIPN.

KW - Chemotherapy

KW - Peripheral neuropathy

KW - Disability evaluation

KW - Patient questionnaire

U2 - 10.1016/j.ejca.2013.04.004

DO - 10.1016/j.ejca.2013.04.004

M3 - Article

C2 - 23668917

SN - 0959-8049

VL - 49

SP - 2910

EP - 2918

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 13

ER -

Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS)

Abstract

Keywords

Access to Document

Fingerprint

Cite this